Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 1, 2007, Pages 7-17

  Prijovich, Zeljko M ^a,b   Leu, Yu Lin ^c   Roffler, Steve R ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

Author keywords

Glucuronidase; 9 Aminocamptothecin; Cancer therapy; Human serum albumin; pH; Prodrug

Indexed keywords

9 AMINOCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN GLUCURONIDE; BETA GLUCURONIDASE; CAMPTOTHECIN DERIVATIVE; HUMAN SERUM ALBUMIN; IRINOTECAN; LACTONE; PRODRUG; TOPOTECAN; UNCLASSIFIED DRUG;

ACIDITY; ALKALINITY; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CELL SURFACE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG PROTEIN BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG CANCER; MICROFILTRATION; PH; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCURONIDASE; GLUCURONIDES; HUMANS; HYBRIDOMAS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; IMMUNOCONJUGATES; INHIBITORY CONCENTRATION 50; LACTONES; MOLECULAR STRUCTURE; PRODRUGS; SERUM ALBUMIN; THYMIDINE; TIME FACTORS; TOPOTECAN; TRITIUM;

EID: 34247390649     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0340-4     Document Type: Article

References (67)

1. Wall ME, Wani M, Cook C, Palmar K, McPhail AT, Sim GA (1966) Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Acuminata. J Am Chem Soc 88:3888-3890
2. Fassberg J, Stella VJ (1992) A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81:676-684
3. Giovanella BC, Harris N, Mendoza J, Cao Z, Liehr J, Stehlin JS (2000) Dependence of anticancer activity of camptothecins on maintaining their lactone function. Ann N Y Acad Sci 922:27-35
4. Burke TG, Mi Z (1993a) Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem 212:285-287
5. Burke TG, Munshi CB, Mi Z, Jiang Y (1995) The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 84:518-519
6. Fleury F, Kudelina I, Nabiev I (1997) Interactions of lactone, carboxylate and self-aggregated forms of camptothecin with human and bovine serum albumins. FEBS Lett 406:151-156
7. Mi Z, Burke TG (1994a) Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study. Biochemistry 33:12540-12545
8. Prijovich ZM, Leu YL, Roffler SR (2003) Stability of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in the presence of human serum albumin. Biochem Pharmacol 66:1181-1187
9. Mi Z, Burke TG (1994b) Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33:10325-10336
10. Loos WJ, Verweij J, Gelderblom HJ, de Jonge MJ, Brouwer E, Dallaire BK, Sparreboom A (1999) Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans. Anticancer Drugs 10:705-710
11. Schnitzer JE, Oh P (1992) Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium. Am J Physiol 263:H1872-H1879
12. Tiruppathi C, Finnegan A, Malik AB (1996) Isolation and characterization of a cell surface albumin-binding protein from vascular endothelial cells. Proc Natl Acad Sci USA 93:250-254
13. Gradishar WJ (2006) Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7:1041-1053
14. Gottlieb JA, Luce JK (1972) Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56:103-105
15. Moertel C, Schutt A, Reitemeier R, Hahn R (1972) Phase II study off camptothecin (NSC-100880) in the treatment off advanced gastrointestinal cancer. Cancer Chemother Rep 56:95-101
16. Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56:515-521
17. Hsiang YH, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726
18. Del Bino G, Lassota P, Darzynkiewicz Z (1991) The S-phase cytotoxicity of camptothecin. Exp Cell Res 193:27-35
19. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M (1989) DNA topoisomerase I - targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048
20. Hsiang Y HR, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878
21. Gao H, Zhang X, Chen Y, Shen H, Pang T, Sun J, Xu C, Ding J, Li C, Lu W(2005) Synthesis and antitumor activity of the hexacyclic camptothecin derivatives. Bioorg Med Chem Lett 15:3233-3236
22. Bom D, Curran DP, Kruszewski S, Zimmer SG, Thompson SJ, Kohlhagen G, Du W, Chavan AJ, Fraley KA, Bingcang AL et al (2000) The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 43:3970-3980
23. Caiolfa VR, Zamai M, Fiorino A, Frigerio E, Pellizzoni C, d'Argy R, Ghiglieri A, Castelli MG, Farao M, Pesenti E et al (2000) Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. J Control Release 65:105-119
24. Lerchen HG, Baumgarten J, von dem Bruch K, Lehmann TE, Sperzel M, Kempka G, Fiebig HH (2001) Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents. J Med Chem 44:4186-4195
25. Daud A, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti RC, Berghorn E, Liu Z et al (2005) Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res 11:3009-3016
26. Cersosimo RJ (1998a) Topotecan: a new topoisomerase I inhibiting antineoplastic agent. Ann Pharmacother 32:1334-1343
27. Cersosimo RJ (1998b) Irinotecan: a new antineoplastic agent for the management of colorectal cancer. Ann Pharmacother 32:1324-1333
28. Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C (1999) Topotecan - a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56:1-12
29. Wani MC, Nicholas AW, Manikumar G, Wall ME (1987a) Plant antitumor agents. 25. Total synthesis and antileukemic activity of ring a substituted camptothecin analogues. Structure-activity correlations. J Med Chem 30:1774-1779
30. Wani MC, Nicholas AW, Wall ME (1987b) Plant antitumor agents. 28. Resolution of a key tricyclic synthon, 5′(RS)-1,5-dioxo-5′-ethyl- 5′-hydroxy-2′H,5′H,6′H-6′-oxopyrano[3′, 4′-f]delta 6,8-tetrahydro-indolizine: total synthesis and antitumor activity of 20(S)- and 20(R)-camptothecin. J Med Chem 30:2317-2319
31. Li ML, Horn L, Firby PS, Moore MJ (2001) Pharmacological determinants of 9-aminocamptothecin cytotoxicity. Clin Cancer Res 7:168-174
32. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R, Potmesil M (1991) Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51:3052-3055
33. Eder JP, Rubin E, Stone R, Bryant M, Xu G, Supko J, Kinchla N, Lynch T, Hurwitz S, Rodriguez D, Shapiro C, Toppmeyer D, Grossbard M, Vosburg E, Huberman M, Schnipper L, Shulman L, Kufe DW (1996) Trials of 9-amino-20(S)-camptothecin in Boston. Ann NY Acad Sci 803:247-255
34. Rubin E, Wood V, Bharti A, Trites D, Lynch C, Hurwitz S, Bartel S, Levy S, Rosowsky A, Toppmeyer D (1995) A phase I and pharmacokinetic study of a new camptothecin derivative, 9-Aminocamptothecin. Clin Cancer Res 1:269-276
35. Potmesil M, Arbuck SG, Takimoto CH, Liebes L, Hochster H (1996) 9-Aminocamptothecin and beyond. Ann NY Acad of Sci 803:231-246
36. Leu YL, Roffler SR, Chern JW (1999) Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem 42:3623-3628
37. Bagshawe KD (1987) Antibody directed enzyme revive anticancer prodrugs concept. 56:531-532
38. Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG, Sherwood RF (1988) A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 58:700-703
39. Prijovich ZM, Chen B-M, Leu Y-L, Chern J-W, Roffler SR (2002) Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice. Br J Cancer 86:1634-1638
40. Bicker U (1974) Application of beta-D-glucuronides and glucose together suggests a new direction for cancer chemotherapy. Nature 252:726-727
41. Rubin DM, Rubin EJ (1980) A minimal toxicity approach to cancer therapy: possible role of beta-glucuronidase. Med Hypotheses 6:85-92
42. Tannock IF, Rotin D (1989) Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49:4373-4384
43. Monson TP, Henle KJ, Nagle WA, Mansouri A (1991) Tumor-targeted delivery of 8-hydroxyquinoline. Int J Radiat Oncol Biol Phys 20:1263-1271
44. Kuin A, Smets L, Volk T, Paans A, Adams G, Atema A, Jahde E, Maas A, Rajewsky MF, Visser G (1994) Reduction of intratumoral pH by the mitochondrial inhibitor m-iodobenzylguanidine and moderate hyperglycemia. Cancer Res 54:3785-3792
45. Zhou R, Bansal N, Leeper DB, Glickson JD (2000) Intracellular acidification of human melanoma xenografts by the respiratory inhibitor m-iodobenzylguanidine plus hyperglycemia: a 31P magnetic resonance spectroscopy study. Cancer Res 60:3532-3536
46. Gabr A, Kuin A, Aalders M, El Gawly H, Smets LA (1997) Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. Cancer Res 57:4811-4816
47. Flowers JL, Hoffman RM, Driscoll TA, Wall ME, Wani MC, Manikumar G, Friedman HS, Dewhirst M, Colvin OM, Adams DJ (2003) The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. Cancer Chemother Pharmacol 52:253-261
48. Kobayashi K, Bouscarel B, Matsuzaki Y, Ceryak S, Kudoh S, Fromm H (1999) pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells. Int J Cancer 83:491-496
49. Ho KJ, Kuo SH (1995) Urinary beta-glucuronidase activity as an initial screening test for urinary tract malignancy in high risk patients. Comparison with conventional urine cytologic evaluation. Cancer 76:473-478
50. Yang PC, Luh KT, Wu R, Wu CW (1992) Characterization of the mucin differentiation in human lung adenocarcinoma cell lines. Am J Respir Cell Mol Biol 7:161-171
51. Cheng TL, Chen BM, Chan LY, Wu PY, Chern JW, Roffler SR (1997) Poly(ethylene glycol) modification of betaglucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs. Cancer Immunol Immunother 44:305-315
52. Milenic DE, Esteban JM, Colcher D (1989) Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72.3) reactive with human carcinomas. J Immunol Methods 120:71-83
53. Cheng TL, Chen BM, Chern JW, Wu MF, Roffler SR (2000) Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug Chem 11:258-266
54. Liao KW, Chen BM, Liu TB, Tzou SC, Lin YM, Lin KF, Su CI, Roffler SR (2003) Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity. Cancer Gene Ther 10:779-790
55. Kohn RA, Dunlap TF (1998) Calculation of the buffering capacity of bicarbonate in the rumen and in vitro. J Anim Sci 76:1702-1709
56. Zunino F, Pratesi G (2004) Camptothecins in clinical development. Expert Opin Investig Drugs 13:269-284
57. Burke TG, Mi Z (1993b) Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin. J Med Chem 36:2580-2582
58. Mi Z, Malak H, Burke TG (1995) Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry 34:13722-13728
59. Garcia-Carbonero R, Supko JG (2002) Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8:641-661
60. Adams DJ, Wahl ML, Flowers JL, Sen B, Colvin M, Dewhirst MW, Manikumar G, Wani MC (2006) Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient. Cancer Chemother Pharmacol 57:145-154
61. Haisma HJ, Boven E, van Muijen M, de Jong J, van der Vijgh WJ, Pinedo HM (1992) A monoclonal antibody-betaglucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br J Cancer 66:474-478
62. Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, Kroemer HK, Gesson JP, Koch M, Monneret C (1998) Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 58:1195-1201
63. Wang SM, Chern JW, Yeh MY, Ng JC, Tung E, Roffler SR (1992) Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res 52:4484-4491
64. Bosslet K, Czech J, Hoffmann D (1994) Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res 54:2151-2159
65. Chen BM, Cheng TL, Tzou SC, Roffler SR (2001) Potentiation of antitumor immunity by antibody-directed enzyme prodrug therapy. Int J Cancer 94:850-858
66. Chen BM, Chan LY, Wang SM, Wu MF, Chern JW, Roffler SR (1997) Cure of malignant ascites and generation of protective immunity by monoclonal antibody-targeted activation of a glucuronide. Int J Cancer 73:392-402
67. Chen KC, Cheng TL, Leu YL, Prijovich ZM, Chuang CH, Chen BM, Roffler SR (2006) Membrane-localized activation of glucuronide prodrugs by β-glucuronidase enzymes. Cancer Gene Ther (in press)